Dengue fever after coronary artery bypass grafting with ventricular dysfunction

Abstract

A 67-year-old man who had undergone a percutaneous coronary intervention, presented with cardiac symptoms. He was managed for acute coronary syndrome and left ventricular dysfunction. After stabilization, he underwent coronary artery bypass grafting but developed dengue hemorrhagic fever postoperatively. He was monitored for hematocrit, platelet count, liver enzymes, and daily fluid balance. His platelet count fell below 40,000/µL, and due to the increased risk of bleeding, warfarin was discontinued and single antiplatelet therapy (aspirin) was continued. After 2 weeks, parameters had normalized. Regular monitoring of hematocrit, platelet count, liver enzymes, and fluid balance played a vital role in the patient’s successful recovery.

Preliminary identification of potential phytochemical components as antiviral agents against Dengue Virus 2: An <i>in silico</i> study

“…There are no specific antiviral drugs against the dengue virus. The treatment is mainly mediated by maintaining the fluid balance to prevent dehydration (K. Gupta et al, 2021;Rajapakse, 2011). Aspirin, other salicylates, and non-steroidal anti-inflammatory drugs (NSAIDs) are fatal as the infecting organism affects the platelets.…”